Keywords: Alnylam, Takeda, RNAi, Oncology, Metabolic disease, Payment

Alnylam earns $10 million from Takeda alliance

Article | 29 March 2011

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) says that it has earned a $10 million technology transfer payment from Japan& ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Alnylam Pharmaceuticals

Takeda Pharmaceuticals

Go to company listing